ORIGINAL ARTICLE. Chemoradiation for Locally Advanced Squamous Cell Carcinoma of the Head and Neck for Organ Preservation and Palliation
|
|
- Stephany Lambert
- 5 years ago
- Views:
Transcription
1 ORIGINAL ARTICLE Chemoradiation for Locally Advanced Squamous Cell Carcinoma of the Head and Neck for Organ Preservation and Palliation Michael E. Poole, PA-C, MPH; Scott L. Sailer, MD; Julian G. Rosenman, MD; Joel E. Tepper, MD; Mark C. Weissler, MD; William W. Shockley, MD; Wendell G. Yarbrough, MD; Harold C. Pillsbury III, MD; Michael J. Schell, PhD; Stephen A. Bernard, MD Objectives: To measure the efficacy and toxic effects of our chemoradiotherapy regimen by means of response and survival in patients with advanced squamous cell carcinoma of the head and neck (HNSCC) for organ preservation in resectable disease or palliation in unresectable disease. Design: All patients underwent evaluation by the multidisciplinary head and neck cancer team, with pathological diagnosis and staging. All patients underwent assessment for response to therapy using results of physical examination and radiologic imaging. Patients were followed up at 3-month intervals for a planned period of 5 years. Setting: Academic center. Patients: Thirty-eight previously untreated patients with newly diagnosed HNSCC were treated from June 1, 1996, through December 31, 1998, of whom had resectable and 18 had unresectable tumors. Intervention: Patients received intravenous cisplatin, mg/m 2 for 1 hour on days 1 and 29; a 24-hour continuous infusion of fluorouracil, 0 mg/m 2 on days 1 through 4 and 29 through 32; and radiation therapy, 150 rad twice daily for 12 days. The patients were given a 7- to 10-day break, and radiation therapy was restarted on day 29 for 12 additional days (total dose, 70 rad). Main Outcome Measures: Complete, partial, and total response rates; disease-free survival; overall survival; and toxic effects. Results: Toxic effects of treatment were moderately severe, including grades III to IV mucositis (89%), neutropenia (71%), and renal toxic effects (8%). In the 18 patients in the unresectable group, complete response in the 17 primary tumors and 15 cervical nodal metastases was achieved in 12 (71%) and 9 (%), respectively; in the patients undergoing organ preservation, complete response rates were % in the 23 primary tumors and 15 cervical nodal metastases. Complete response for all 38 patients was achieved in 31 (82%). In the unresectable group, the Kaplan-Meier relapse-free survival estimate is 56%, with follow-up from 29 to 45 months. In the organ preservation group, 75% of patients are alive without disease, and 8 have been followed up for 36 to 48 months. Of the 5 patients who have died, only 2 died of disease, with recurrences at 13.0 and 16.5 months. Conclusions: Chemoradiotherapy consisting of cisplatin, fluorouracil, and twice-daily external beam radiation is highly effective in achieving durable complete responses in patients with resectable HNSCC undergoing organ preservation and patients with unresectable HNSCC undergoing palliation. Toxic effects of this regimen were moderate to severe. Arch Otolaryngol Head Neck Surg. 01;127: From the Division of Hematology/Oncology, Department of Medicine (Mr Poole and Dr Bernard), and the Departments of Radiation Oncology (Drs Sailer, Rosenman, and Tepper) and Otolaryngology Head and Neck Surgery (Drs Weissler, Shockley, Yarbrough, and Pillsbury), University of North Carolina School of Medicine, and the University of North Carolina Lineberger Comprehensive Cancer Center (Dr Schell), Chapel Hill. HEAD AND NECK squamous cell carcinoma (HNSCC) constitutes 5% of all cancers in the United States, with approximately new cases and deaths per year. Most of these cancers originate in the oral cavity, but the larynx is the most common specific anatomical site. Two thirds of new cases present with advanced local disease and/or regional lymph node involvement, and 10% to % present with distant metastasis. Locoregional recurrence after therapy is noted in % of patients with advanced disease. 1-3 Standard therapy for locally advanced HNSCC has been surgery and radiation. However, these treatment modalities are associated with significant morbidity. Chemotherapy has been reserved for palliation of unresectable, recurrent, or metastatic disease. The combination of cisplatin and fluorouracil routinely provides a response rate of approximately 85%, with a complete response (CR) rate of 35%. 3,4 In recent years, chemotherapy has been used in the neoadjuvant or induction setting in an attempt to increase overall survival by increasing locoregional control or by eradicating micrometastases. Concomitant che- 1446
2 PATIENTS AND METHODS Patients with locally advanced and/or metastatic, newly diagnosed, previously untreated HNSCC underwent evaluation by specialists in otolaryngology head and neck surgery, radiation oncology, and medical oncology and were presented at a multidisciplinary conference. All patients underwent panendoscopy, computed tomographic scanning and/or magnetic resonance imaging, and dental evaluation and were classified according to the system of the American Joint Committee on Cancer Staging. 6 All computed tomographic and magnetic resonance imaging scans were read by a single radiologist who is a specialist in head and neck radiology. Criteria for treatment included being older than 18 years and having an Eastern Cooperative Oncology Group performance status of 0 (fully active) to 2 (ambulatory and capable of all self-care, but unable to carry out any work activities), no previous chemotherapy or radiation therapy to the head and neck, white blood cell count of greater than 00 cells/µl, platelet count of greater than 000 cells/µl, and serum creatinine level of less than 2.0 mg/dl (177 µmol/l). The group with resectable disease, treated for organ preservation, consisted mainly of patients with primary tumors in the base of the tongue or hypopharynx, but other primary sites were also treated for patients who were considered to be at poor surgical risk or who refused surgery as primary therapy. Tumors were considered to be unresectable if they involved the base of the skull, carotid artery, vertebral bone, or prevertebral musculature. All patients were treated using an institutional regimen based on the literature, and data were collected and analyzed after approval by the institutional review board. Chemotherapy consisted of intravenous cisplatin, mg/m 2 for 1 hour on days 1 and 29, and continuous infusion of fluorouracil, 0 mg/m 2 for 24 hours on days 1 through 4 and 29 through 32. All patients received prehydration using intravenous dextrose 5% and 0.45% isotonic sodium chloride, 250 ml/h for 4 hours, with intravenous mannitol, 12.5 g, given before cisplatin therapy. Posthydration was provided during daily fluorouracil administration as a 2-L continuous infusion of dextrose 5% and 0.45% isotonic sodium chloride. Antiemetics consisted of 2 mg of oral granisetron hydrochloride and mg of intravenous dexamethasone sodium phosphate given before cisplatin therapy on day 1, then 10 mg of intravenous prochlorperazine maleate every 6 hours. Intravenous lorazepam, 1 mg every 8 hours, was given as needed for nausea and/or vomiting. Gastrostomy tubes were recommended for all patients with oral cavity, oropharyngeal, hypopharyngeal, and laryngeal primary tumors to provide adequate hydration and nutrition. Radiation therapy was administered using a 6-MeV linear accelerator. All patients received 150 rad per fraction twice a day on days 1 through 12, with a minimum of 6 hours between fractions. After a dose of 3000 to 30 rad, the patients received a 10-day treatment break, and radiation therapy was then restarted concomitantly with chemotherapy on day 29, to an average total dose of 70 rad. Total treatment time for all patients was 6 to 7 weeks. All patients underwent assessment for response to therapy. Kaplan-Meier curves were used to plot the relapsefree survival and overall survival for the resectable (organ preservation) and unresectable (palliation) groups from the end of therapy. In the relapse-free survival estimates, patients who were lost to follow-up and those who died without disease are censored at that point and are denoted by symbols on the graphs, but are not included in the survival calculations. Treatment of patients not rendered disease-free was considered to have failed at time 0. In the overall survival estimates, deaths due to all causes are included in the calculations, and those who died without disease are denoted by a symbol at that point. Patients who were lost to follow-up are denoted by a symbol at that point, but are not included in the overall survival calculations. moradiotherapy for organ preservation has proved to be an effective approach in achieving a high and durable CR rate without surgical resection. 5 In June 1996, a chemoradiotherapy regimen for advanced HNSCC consisting of cisplatin, fluorouracil, and twice-daily radiation was instituted as standard therapy for organ preservation of resectable disease and aggressive palliation of unresectable disease. This report presents the data from the first 38 patients treated with this aggressive regimen. The demographic, response, and survival data for the patients with unresectable and resectable disease have been calculated separately to allow comparison between both groups and with similar patient populations described elsewhere. RESULTS From June 1, 1996, until December 31, 1998, 38 patients with primary tumors were treated with chemoradiotherapy. Eighteen patients with unresectable disease received palliative therapy (unresectable group), and patients with resectable disease received organ preservation therapy (organ preservation group). The male-female ratio was 3.2:1.0; white-black race ratio,1.1:1.0. Mean age was 55.5 years (range, years). The patient and tumor characteristics for each group are shown in Table 1. The sex ratio was essentially equal in each group, but the racial composition was reversed between the 2 groups, with 12 black and 6 white patients in the unresectable group and 6 black and 14 white patients in the organ preservation group. In the unresectable group, 10 (56%) of the 18 patients presented with T4 primary tumors. Three patients in the organ preservation group had synchronous primary tumors, with 11 (48%) of 23 primary tumors staged as T3. Of the 38 patients, 30 (79%) presented with nodal disease. In the unresectable group, 11 (61%) of 18 had N3 disease ( 6 cm in greatest dimension). All patients in the unresectable group and 14 (70%) of in the organ preservation group had stage IV disease. Seven (18%) of the 38 patients were not able to complete the full course of therapy and required an alteration in the treatment. In 4 (11%) of 38 patients, the second course of chemotherapy was omitted because of various toxic effects, including severe mucositis, moderate renal toxic effects, and decreased performance status, but the radiation therapy was completed in all 4 patients. In 3 (8%) of 38 patients, carboplatin (area under the curve, 5) was substituted for cisplatin on day 29 owing to mild renal toxic effects. The response rates for each 1447
3 Table 1. Patient and Tumor Characteristics* Study Groups Organ Characteristic Unresectable Preservation Total Total patients, No. (%) 18 (47) (53) 38 () Sex, No. male/female 14/4 15/5 3.2/1.0 Age, y Mean Range Race, No. black/white 12/6 6/14 1.1/1.0 Sites of primary tumor Base of tongue 1 (6) 6 (26) 7 (18) Tonsil 4 (24) 1 (4) 5 (13) Piriform sinus 2 (12) 4 (17) 6 (15) Vallecula 2 (12) 2 (9) 4 (10) False vocal cord 0 3 (13) 3 (8) Tongue 0 3 (13) 3 (8) Epiglottis 1 (6) 1 (4) 2 (5) Pharyngeal wall 1 (6) 1 (4) 2 (5) Other 6 (35) 2 (9) 8 () Tumor size TX 0 2 (9) 2 (5) TO 1 (6) 0 1 (3) TIS 1 (6) 0 1 (3) T1 3 (17) 2 (9) 5 (13) T2 2 (11) 5 (23) 7 (18) T3 1 (6) 10 (45) 11 (28) T4 10 (56) 3 (14) 13 (33) Lymph node status N0 3 (17) 5 (25) 8 (21) N1 0 2 (10) 2 (5) N2a N2b 1 (6) 8 () 9 (24) N2c 3 (17) 3 (15) 6 (16) N3 11 (61) 2 (10) 13 (34) Stage III 0 6 (30) 6 (16) IV 18 () 14 (70) 32 (84) *Tumor and nodal stages are defined by the American Joint Committee for Cancer Staging and End Result Reporting for head and neck cancer, in Fleming et al. 6 Data are given as number (percentage) unless otherwise indicated. Percentages have been rounded and may not sum to. group were calculated based on an intent-to-treat basis and are shown in Table 2. Two patients were lost to follow-up, and one of these received only 1 week of therapy. Findings in these 2 patients were considered nonevaluable, and were included in the denominators of the response rates but not in the survival calculations. Response data are presented in Table 2. In the unresectable group, the CR rates of the primary tumors and the cervical nodal metastases were 71% and %, respectively. In the organ preservation group, the CR rates were % for the primary tumors and the nodal metastases. When both groups were combined, the CR rate was 35 (88%) of for the primary tumors and 24 (%) of 30 for the cervical nodal metastases. The total CR rate for all 38 patients was 31 (82%). Among patients who achieved a CR, neck dissections were performed at approximately 8 weeks after completion of therapy for 2 patients in the unresectable group with N3 disease and in 5 patients in the organ preservation group with N2c to N3 disease. Results of pathological examination of all of these dissection specimens were negative for metastatic disease. Based on these results, it was decided that neck dissections would be performed only in the organ preservation group patients with a node measuring 3 cm or greater at diagnosis and who had residual neck disease at the end of therapy. The Kaplan-Meier estimates of relapse-free survival and overall survival data for both groups are displayed in Figures 1, 2, 3, and 4 and Table 3. As of September 30, 00, 8 of 18 patients in the unresectable group have died with disease at 1, 4, 6, 7, 8, 10, 14, and 19 months since the completion of therapy, for a relapse-free survival estimate of 56%. One patient died without disease at 13 months and 2 patients were lost to follow-up at 5.0 and 7.5 months. Six patients (33%) were alive without disease and have been observed for 29 to 45 months. In the organ preservation group, 2 of patients have died with disease at 19 and 33 months, for a relapse-free survival estimate of 90%. Three patients have died without disease of recurrent vaginal cancer, ischemic heart disease, and lung cancer at 8.5, 27, and 37 months, respectively. Fifteen patients (75%) were alive without disease, with 8 of these having been observed for 36 to 48 months. Toxic effects were graded according to the National Cancer Institute s Common Toxicity Criteria, and the combined data of both groups are shown in Table 4. Grades III to IV neutropenia occurred in 27 (71%) of 38 patients, with 15 (39%) requiring hospital admission for fever and treatment with intravenous antibiotics. Thirtyfour patients (89%) experienced grades III to IV mucositis, and 22 (58%) had gastrostomy tubes placed before treatment for nutrition and hydration. The average weight loss during therapy was 6.8 kg. Nausea and vomiting were mild to moderate in most patients, with only 1 patient experiencing intractable nausea. Four patients who did not present with dysphagia continued to experience severe dysphagia after therapy. Grades I to II renal toxic effects were seen in 8 (21%) of 38 patients, and grades III to IV effects in 3 patients (8%). There was 1 case of sepsis requiring admission to the intensive care unit and discontinuation of therapy, and 1 case of pulmonary aspergillosis, which was successfully treated. COMMENT This chemoradiotherapy regimen was associated with significant toxic effects requiring aggressive supportive care, but it also provides a high response rate, even in patients with bulky, unresectable disease. Adelstein 7 published a review of randomized trials of chemoradiotherapy for HNSCC in May 1998, which concluded that chemoradiotherapy improves overall survival and locoregional control through radiosensitization and offers the advantages of decreased duration of treatment and a lower rate of distant metastases. A previous study by Adelstein et al 8 compared multiagent chemotherapy and radiation therapy with radiation therapy alone. One hundred patients with advanced, resectable disease were randomized to chemoradiotherapy with fluorouracil and cisplatin or to radiation therapy alone. Seventy-six percent of the patients receiving chemoradiotherapy achieved a CR, compared with 50% of the patients who received radiation therapy only. Relapse-free survival at 36 months was 67% and 52%, respectively, and the dis- 1448
4 Table 2. Response to Therapy* Unresectable Group Organ Preservation Patients (n = ) Combined Response Rates (n = 38) Response (n = 17) (n = 15) (n = 23) (n = 15) (n = ) (n = 30) CR 12 (71) 9 () 23 () 15 () 35 (88) 24 () PR 1 (6) 4 (27) (2) 4 (13) MR 1 (6) (2) 0 NE 3 (18) 2 (13) (8) 2 (7) *Data are given as number (percentage) of tumors. CR indicates complete response; PR, partial response; MR, minimal response; and NE, nonevaluable. Percentages have been rounded and may not sum to. Study groups are described in the Patients and Methods section. One primary tumor was unknown; clinically negative results were found in 4 nodes. Complete response was achieved in 11 (65%) of 17 patients. Two primary tumors were unevaluable; clinically negative results were found in 4 nodes. Complete response was achieved in (%) of patients. Complete response was achieved in 31 (82%) of 38 patients. Relapse-Free Survival, % Overall Survival, % Figure 1. Kaplan-Meier estimates of relapse-free survival for patients in the organ preservation group from the end of therapy for patients achieving a complete response. Circles indicate patients who died without disease and were censored at the time of death. Study groups are described in the Patients and Methods section. Figure 3. Kaplan-Meier estimates of overall survival for patients in the organ preservation group from the end of therapy. Deaths due to all causes were included in the analysis. Circles indicate patients who died without disease and were censored at the time of death. Study groups are described in the Patients and Methods section. Relapse-Free Survival, % Overall Survival, % Figure 2. Kaplan-Meier estimates of relapse-free survival for patients in the unresectable group from the end of therapy for patients achieving a complete response. Circles indicate patients who died without disease and were censored at the time of death; triangles, patients who were lost to follow-up. Study groups are described in the Patients and Methods section Figure 4. Kaplan-Meier estimates of overall survival for patients in the unresectable group from the end of therapy for all patients. Deaths due to all causes were included in the analysis. Circles indicate patients who died without disease and were censored at the time of death; triangles, patients who were lost to follow-up. Study groups are described in the Patients and Methods section. tant metastasis rates were 10% and 21%, respectively. In that study, 8 overall survival was not significantly different for the 2 groups, but additional follow-up was required for accurate assessment due to the number of patients with recurrent disease remaining alive at the time of publication. In April 1998, Wendt et al 9 published a prospective, randomized, multicenter study to evaluate chemoradiotherapy compared with radiation therapy alone as primary therapy for unresectable disease. In the 270 patients with evaluable results, 130 received chemoradiotherapy con- 1449
5 Table 3. Survival Status* Table 4. Maximum Acute Toxic Effects During Therapy (N = 38)* Common Toxic Effects Criteria, Grade Effect 0 I II III IV Mucositis Neutropenia Renal *Data are given as number of patients. Study Group Organ Status Unresectable Preservation Total Alive without disease 6 (33) 15 (75) 21 (55) Alive with disease 1 (6) 0 1 (3) Died without disease 1 (6) 3 (15) 4 (11) Died with disease 8 (44) 2 (10) 10 (26) Died toxicity Nonevaluable 2 (11) 0 2 (5) *Data are given as number (percentage) of patients. Study groups are described in the Patients and Methods section. sisting of cisplatin, fluorouracil, and leucovorin calcium, and the remaining 1 received radiation therapy alone. The Kaplan-Meier estimates for 3-year locoregional control were 35% and 17%, respectively, and the estimates for overall survival were 49% and 24%, respectively. 9 Brizel et al 10 described 122 patients treated in a randomized study in June Their study used chemoradiotherapy consisting of cisplatin, 12 mg/m 2 per day for 5 days, and fluorouracil, 0 mg/m 2 per day for 5 days during weeks 1 and 6, with 2 additional adjuvant courses. This regimen was compared with radiation therapy alone (125 rad twice daily) as primary therapy in patients with locally advanced disease, which was unresectable in 53%. Eighty-eight percent of the patients receiving chemoradiotherapy achieved a CR, compared with 73% in the radiation therapy group. The patients who received chemoradiotherapy also had improved locoregional control (70% vs 44%), relapse-free survival (61% vs 41%), and overall survival (55% vs 34%) at 3 years compared with the patients who received radiation therapy alone. Fifty (89%) of 56 patients in the chemoradiotherapy group in the study by Brizel et al 10 had T3 and T4 primary tumors, compared with 24 (63%) of our 38 patients; however, only 7 (13%) of 56 patients in the chemoradiotherapy group in the study by Brizel et al presented with N3 neck disease, compared with 11 (30%) of our patients. In our unresectable group, 11 (61%) of 18 patients presented with N3 neck disease. Seven (64%) of these 11 patients achieved a CR in the neck, and most of these responses have been durable, with no recurrences in 5 patients after 29 to 48 months of follow-up. One patient died at 16.5 months without disease; 1 patient had a local recurrence at 9.5 months, and another patient had a distal recurrence at 1 month without cervical node recurrence after 36 months. The study by Brizel et al 10 used a lower total dose of cisplatin ( mg/m 2 ) and fluorouracil (3000 mg/m 2 ) for 2 courses and a lower twice-daily fraction of radiation (125 rad) than our regimen. Their percentage of patients with mucositis was similar, but the percentage of patients requiring admission for fever and neutropenia was significantly higher in our report (39% vs 14%). It may be appropriate to consider modifying the therapy by using lower doses of chemotherapy and radiation therapy (per fraction) for patients with resectable tumors undergoing organ preservation to decrease the toxic effects, reserving our current regimen for patients with bulky, unresectable tumors for aggressive palliation. CONCLUSIONS Chemoradiotherapy consisting of cisplatin, fluorouracil, and twice-daily radiation is extremely effective therapy for locally advanced HNSCC in organ preservation and palliation. Its efficacy is most notable in the high rate of durable CRs in patients with advanced resectable disease. This intensive regimen increases the risk for significant toxic effects, especially fever, neutropenia, and mucositis; therefore, aggressive supportive care is essential. We will continue to follow up these patients for survival and long-term toxic effects. Accepted for publication July 25, 01. Preliminary data presented in poster form at American Society of Clinical Oncology conference, Los Angeles, Calif, May 18, Corresponding author and reprints: Michael E. Poole, PA-C, MPH, Division of Hematology/Oncology, 3009 Old Clinic Bldg, CB 7305, University of North Carolina School of Medicine, Chapel Hill, NC ( poolem@med.unc.edu). REFERENCES 1. Stupp R, Chung TDK, Collins SL, Dougherty MJ, Weichselbaum RR, Vokes EE. Head and neck. In: Abeloff M, Armitage J, Lichter A, Niederhuber J, eds. Clinical Oncology. New York, NY: Churchill Livingstone Inc; 00: Lane M, Donovan DT. Neoplasms of the head and neck. In: Calabresi P, Schein P, eds. Medical Oncology. New York, NY: McGraw-Hill Co; 1993: Forastiere AA. Overview of platinum chemotherapy in head and neck cancer. Semin Oncol. 1994;21: Jacobs C, Lyman G, Velez-Garcia E, et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol. 1992;10: Vokes E, Weichselbaum RR. Concomitant chemoradiotherapy: rationale and clinical experience in patients with solid tumors. J Clin Oncol. 1990;8: Fleming ID, Cooper JS, Henson DE, et al, eds. American Joint Committee on Cancer Staging Manual. 5th ed. Philadelphia, Pa: Lippincott William & Wilkins; Adelstein DJ. Recent randomized trials of chemoradiation in the management of locally advanced head and neck cancer. Curr Opin Oncol. 1998;10: Adelstein DJ, Saxton JP, Lavertu P, et al. A phase III randomized trial comparing concurrent chemotherapy and radiotherapy with radiotherapy alone in resectable stage III and IV squamous cell head and neck cancer: preliminary results. Head Neck. 1997;19: Wendt TG, Grabenbauer GG, Rodel CM, et al. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. J Clin Oncol. 1998;16: Brizel DM, Albers ME, Fisher SR, et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med. 1998;338:
Title. CitationInternational Journal of Clinical Oncology, 20(6): 1. Issue Date Doc URL. Rights. Type. File Information
Title Clinical outcomes of weekly cisplatin chemoradiother Sakashita, Tomohiro; Homma, Akihiro; Hatakeyama, Hir Author(s) Takatsugu; Iizuka, Satoshi; Onimaru, Rikiya; Tsuchiy CitationInternational Journal
More informationSelf-Assessment Module 2016 Annual Refresher Course
LS16031305 The Management of s With r. Lin Learning Objectives: 1. To understand the changing demographics of oropharynx cancer, and the impact of human papillomavirus on overall survival and the patterns
More informationORIGINAL ARTICLE. Harold Lau, MD; Tien Phan, MD; Jack MacKinnon, MD; T. Wayne Matthews, MD
ORIGINAL ARTICLE Absence of Planned Neck Dissection for the N2-N3 Neck After Chemoradiation for Locally Advanced Squamous Cell Carcinoma of the Head and Neck Harold Lau, MD; Tien Phan, MD; Jack MacKinnon,
More informationORIGINAL ARTICLE. Examining the Need for Neck Dissection in the Era of Chemoradiation Therapy for Advanced Head and Neck Cancer
ORIGINAL ARTICLE Examining the Need for Neck Dissection in the Era of Chemoradiation Therapy for Advanced Head and Neck Cancer Laura A. Goguen, MD; Marshall R. Posner, MD; Roy B. Tishler, MD, PhD; Lori
More informationAccepted 20 April 2009 Published online 25 June 2009 in Wiley InterScience (www.interscience.wiley.com). DOI: /hed.21179
ORIGINAL ARTICLE DOCETAXEL, CISPLATIN, AND FLUOROURACIL INDUCTION CHEMOTHERAPY FOLLOWED BY ACCELERATED FRACTIONATION/CONCOMITANT BOOST RADIATION AND CONCURRENT CISPLATIN IN PATIENTS WITH ADVANCED SQUAMOUS
More informationAccepted 12 April 2006 Published online 13 November 2006 in Wiley InterScience ( DOI: /hed.
ORIGINAL ARTICLE PHASE II ANALYSIS OF PACLITAXEL AND CAPECITABINE IN THE TREATMENT OF RECURRENT OR DISSEMINATED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK REGION Jens D Bentzen, MD, 1 Hanne Sand Hansen,
More informationORIGINAL ARTICLE CHEMOTHERAPY ALONE FOR ORGAN PRESERVATION IN ADVANCED LARYNGEAL CANCER
ORIGINAL ARTICLE CHEMOTHERAPY ALONE FOR ORGAN PRESERVATION IN ADVANCED LARYNGEAL CANCER Vasu Divi, MD, 1 * Francis P. Worden, MD, 1,2 * Mark E. Prince, MD, 1 Avraham Eisbruch, MD, 3 Julia S. Lee, MD, 4
More informationLaryngeal Preservation Using Radiation Therapy. Chemotherapy and Organ Preservation
1 Laryngeal Preservation Using Radiation Therapy 1903: Schepegrell was the first to perform radiation therapy for the treatment of laryngeal cancer Conventional external beam radiation produced disappointing
More informationMANAGEMENT OF CA HYPOPHARYNX
MANAGEMENT OF CA HYPOPHARYNX GENERAL TREATMENT RECOMMENDATIONS BASED ON HYPOPHARYNX TUMOR STAGE For patients presenting with early-stage definitive radiotherapy alone or voice-preserving surgery are viable
More informationTOXICITY OF TWO CISPLATIN-BASED RADIOCHEMOTHERAPY REGIMENS FOR THE TREATMENT OF PATIENTS WITH STAGE III/IV HEAD AND NECK CANCER
ORIGINAL ARTICLE TOXICITY OF TWO CISPLATIN-BASED RADIOCHEMOTHERAPY REGIMENS FOR THE TREATMENT OF PATIENTS WITH STAGE III/IV HEAD AND NECK CANCER Dirk Rades, MD, 1 Fabian Fehlauer, MD, 2 Mashid Sheikh-Sarraf,
More informationRECURRENCE in the neck is a
ORIGINAL ARTICLE Efficacy of Targeted Chemoradiation and Planned Selective Neck Dissection to Control Bulky Nodal Disease in Advanced Head and Neck Cancer K. Thomas Robbins, MD; Frank S. H. Wong, MD; Parvesh
More informationConcurrent chemoradiotherapy for N2 or N3 squamous cell carcinoma of the head and neck from an occult primary
Original article Annals of Oncology 14: 1306 1311, 2003 DOI: 10.1093/annonc/mdg330 Concurrent chemoradiotherapy for N2 or N3 squamous cell carcinoma of the head and neck from an occult primary A. Argiris
More informationCetuximab/cisplatin and radiotherapy in HNSCC: is there a favorite choice?
Cent. Eur. J. Med. 9(2) 2014 279-284 DOI: 10.2478/s11536-013-0154-9 Central European Journal of Medicine Cetuximab/cisplatin and radiotherapy in HNSCC: is there a favorite choice? Jacopo Giuliani* 1, Marina
More informationNeoadjuvant Chemotherapy in Locally Advanced Squamous Cell Cancer of Head and Neck. Mei Tang, MD
Neoadjuvant Chemotherapy in Locally Advanced Squamous Cell Cancer of Head and Neck Mei Tang, MD Head and Neck Cancer Worldwide New cases : 644,000 Cancer deaths: 350,000 About 5% of all cancers Local Recurrence:
More informationThe management of advanced supraglottic and
ORIGINAL ARTICLE ORGAN PRESERVATION FOR ADVANCED LARYNGEAL CARCINOMA Robert L. Foote, MD, 1 R. Tyler Foote, 1 Paul D. Brown, MD, 1 Yolanda I. Garces, MD, 1 Scott H. Okuno, MD, 2 Scott E. Strome, MD 3 1
More informationLaryngeal Conservation
Laryngeal Conservation Sarah Rodriguez, MD Faculty Advisor: Shawn Newlands, MD, PhD The University of Texas Medical Branch Department of Otolaryngolgy Grand Rounds Presentation February 2005 Introduction
More informationResearch Article Planned Neck Dissection Following Radiation Treatment for Head and Neck Malignancy
Hindawi Publishing Corporation International Journal of Otolaryngology Volume 22, Article ID 95423, 5 pages doi:5/22/95423 Research Article Planned Neck Dissection Following Radiation Treatment for Head
More informationORIGINAL ARTICLE. Salvage Surgery After Failure of Nonsurgical Therapy for Carcinoma of the Larynx and Hypopharynx
ORIGINAL ARTICLE Salvage Surgery After Failure of Nonsurgical Therapy for Carcinoma of the Larynx and Hypopharynx Sandro J. Stoeckli, MD; Andreas B. Pawlik, MD; Margareta Lipp, MD; Alexander Huber, MD;
More informationHead and Neck Reirradiation: Perils and Practice
Head and Neck Reirradiation: Perils and Practice David J. Sher, MD, MPH Department of Radiation Oncology Dana-Farber Cancer Institute/ Brigham and Women s Hospital Conflicts of Interest No conflicts of
More informationSurvival impact of cervical metastasis in squamous cell carcinoma of hard palate
Vol. 116 No. 1 July 2013 Survival impact of cervical metastasis in squamous cell carcinoma of hard palate Quan Li, MD, a Di Wu, MD, b,c Wei-Wei Liu, MD, PhD, b,c Hao Li, MD, PhD, b,c Wei-Guo Liao, MD,
More informationEvaluation and Treatment of Dysphagia in the Head and Neck Cancer Patient
Evaluation and Treatment of Dysphagia in the Head and Neck Cancer Patient Linda Stachowiak MS/CCCSLP BCS-S Speech Pathology Oncology Specialist UFHealth Cancer Center at Orlando Health Orlando Florida
More informationNasopharyngeal Cancer/Multimodality Treatment
Nasopharyngeal Cancer/Multimodality Treatment PANAGIOTIS KATSAOUNIS Medical Oncologist IASO GENERAL HOSPITAL Athens, 22/10/2016 1 st Hellenic Multidisciplinary Conference on Head and Neck Cancer INTRODUCTION
More informationTRANSPARENCY COMMITTEE OPINION. 18 October 2006
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 18 October 2006 ERBITUX 2 mg/ml, Solution for infusion 1 bottle of 50 ml (CIP: 565 806 9) Applicant : MERCK LIPHA
More informationNasopharyngeal Cancer:Role of Chemotherapy
Nasopharyngeal Cancer:Role of Chemotherapy PANAGIOTIS KATSAOUNIS Medical Oncologist IASO GENERAL HOSPITAL Athens, 16/9/2017 2 nd Hellenic Multidisciplinary Conference on Head and Neck Cancer INTRODUCTION
More informationAccepted 28 April 2005 Published online 13 September 2005 in Wiley InterScience ( DOI: /hed.
DEFINING RISK LEVELS IN LOCALLY ADVANCED HEAD AND NECK CANCERS: A COMPARATIVE ANALYSIS OF CONCURRENT POSTOPERATIVE RADIATION PLUS CHEMOTHERAPY TRIALS OF THE EORTC (#22931) AND RTOG (#9501) Jacques Bernier,
More information5/20/ ) Haffty GB: Concurrent chemoradiation in the treatment of head and neck cancer. Hematol. Oncol. Clin: North Am.
Prague, 24-25 25 April 29 ALTERNATING CHEMORADIATION: FOR WHOM? M. Merlano MD Holy Cross Gen. Hospital Cuneo - Italy ALTERNATING CHEMORADIATION: FOR WHOM? Definition of alternating chemoradiation Targets
More informationOral cavity cancer Post-operative treatment
Oral cavity cancer Post-operative treatment Dr. Christos CHRISTOPOULOS Radiation Oncologist Centre Hospitalier Universitaire (C.H.U.) de Limoges, France Important issues RT -techniques Patient selection
More informationThe New England Journal of Medicine HYPERFRACTIONATED IRRADIATION WITH OR WITHOUT CONCURRENT CHEMOTHERAPY FOR LOCALLY ADVANCED HEAD AND NECK CANCER
HYPERFRACTIONATED IRRADIATION WITH OR WITHOUT CONCURRENT CHEMOTHERAPY FOR LOCALLY ADVANCED HEAD AND NECK CANCER DAVID M. BRIZEL, M.D., MARY E. ALBERS, M.D., SAMUEL R. FISHER, M.D., RICHARD L. SCHER, M.D.,
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES HEAD AND NECK HYPOPHARYNX Head & Neck Site Group Hypopharynx 1. INTRODUCTION 3 2. PREVENTION 3 3. SCREENING AND EARLY DETECTION 3 4. DIAGNOSIS
More informationOutcomes for patients with head and neck squamous cell carcinoma presenting with N3 nodal disease
Witek et al. Cancers of the Head & Neck (2017) 2:8 DOI 10.1186/s41199-017-0027-z Cancers of the Head & Neck RESEARCH Open Access Outcomes for patients with head and neck squamous cell carcinoma presenting
More informationNew Paradigms for Treatment of. Erminia Massarelli, MD, PHD, MS Clinical Associate Professor
New Paradigms for Treatment of Head and Neck cancers Erminia Massarelli, MD, PHD, MS Clinical Associate Professor City of Hope Disclosure Statement Grant/Research Support frommerck Bristol Grant/Research
More informationComparison of acute toxicities and response of standard chemo radiation versus hyper fractionated radiotherapy in head and neck cancers
Original Research Article Comparison of acute toxicities and response of standard chemo radiation versus hyper fractionated radiotherapy in head and neck cancers Kuppa Prakash 1*, A. Ravi Chandran 2, M.
More information3/12/2018. Head & Neck Cancer Review INTRODUCTION
Head & Neck Cancer Review Joseph Rosales, MD March 12, 2018 INTRODUCTION Epidemiology/Risk Factors Anatomy Presentation/Workup Treatment Surgery vs Radiation Chemotherapy Side effects Special circumstances
More informationManagement of Neck Metastasis from Unknown Primary
Management of Neck Metastasis from Unknown Primary.. Definition Histologic evidence of malignancy in the cervical lymph node (s) with no apparent primary site of original tumour Diagnosis after a thorough
More informationORIGINAL ARTICLE. David E. Schuller, MD; Enver Ozer, MD; Amit Agrawal, MD; John C. Grecula, MD; Chris A. Rhoades, MD; Donn C.
ORIGINAL ARTICLE Multimodal Intensification Regimens for Advanced, Resectable, Previously Untreated Squamous Cell Cancer of the Oral Cavity, Oropharynx, or Hypopharynx A 12-Year Experience David E. Schuller,
More informationNICE guideline Published: 10 February 2016 nice.org.uk/guidance/ng36
Cancer of the upper aerodigestive e tract: assessment and management in people aged 16 and over NICE guideline Published: 10 February 2016 nice.org.uk/guidance/ng36 NICE 2018. All rights reserved. Subject
More informationComparative study of Gemcitabine versus Cisplatin concurrent with radiotherapy for locally advanced head and neck cancer
Journal of Cancer Treatment and Research 2014; 2(4): 37-44 Published online August 30, 2014 (http://www.sciencepublishinggroup.com/j/jctr) doi: 10.11648/j.jctr.20140204.12 Comparative study of Gemcitabine
More informationBCCA Protocol Summary for Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck Cancer Using Fluorouracil and Platinum
BCCA Protocol Summary for Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck Cancer Using Fluorouracil and Platinum Protocol Code: Tumour Group: Contact Physician: HNAVFUP Head and Neck
More informationPILOT STUDY OF CONCURRENT CHEMO-RADIOTHERAPY FOR ADVANCED NASOPHARYNGEAL CARCINOMA (Forum for Nuclear Cooperation in Asia)
PILOT STUDY OF CONCURRENT CHEMO-RADIOTHERAPY FOR ADVANCED NASOPHARYNGEAL CARCINOMA (Forum for Nuclear Cooperation in Asia) Dr. Miriam Joy C. Calaguas Dept. of Radiation Oncology St. Luke s Medical Center
More informationPRINCIPLES OF RADIATION ONCOLOGY
PRINCIPLES OF RADIATION ONCOLOGY Ravi Pachigolla, MD Faculty Advisor: Anna Pou, MD The University of Texas Medical Branch Department of Otolaryngology Grand Rounds Presentation January 5, 2000 HISTORY
More informationCancer of the upper aerodigestive tract: assessment and management in people aged 16 and over
Cancer of the upper aerodigestive tract: assessment and management in people aged and over NICE guideline Draft for consultation, March 0 This guideline covers This guideline covers assessing and managing
More informationHypofractionated palliative radiotherapy for advanced head and neck cancer: The IHF2SQ regimen
ORIGINAL ARTICLE Hypofractionated palliative radiotherapy for advanced head and neck cancer: The IHF2SQ regimen Laurie Monnier, MD, 1 * Emmanuel Touboul, MD, PhD, 1 Catherine Durdux, MD, 2 Philippe Lang,
More informationOncologist. The. Outcomes Research. Changes in Survival in Head and Neck Cancers in the Late 20th and Early 21st Century: A Period Analysis
The Oncologist Outcomes Research Changes in Survival in Head and Neck Cancers in the Late 20th and Early 21st Century: A Period Analysis DIANNE PULTE, a,b HERMANN BRENNER a a Division of Clinical Epidemiology
More informationAlthough esophagectomy remains the standard of care for esophageal
Keresztes et al General Thoracic Surgery Preoperative chemotherapy for esophageal cancer with paclitaxel and carboplatin: Results of a phase II trial R. S. Keresztes, MD J. L. Port, MD M. W. Pasmantier,
More informationPalliative Hypo-fractionated Radiotherapy in Locally Advanced Head and Neck Cancer with Fixed Neck Nodes
Original Article Palliative Hypo-fractionated Radiotherapy in Locally Advanced Head and Neck Cancer with Fixed Neck Nodes Rajan Paliwal 1, Arvind Kumar-Patidar 1, Rahul Walke 1, Pushpendra Hirapara 1,
More informationWeekly Cisplatin + Radiotherapy - Interlace study -
Weekly Cisplatin + Radiotherapy - Interlace study - A phase III multicentre trial of weekly induction chemotherapy followed by standard chemoradiation versus standard chemoradiation alone in patients with
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Robert F. Taylor, MD Aurora Health Care
Immunotherapy for the Treatment of Head and Neck Cancers Robert F. Taylor, MD Aurora Health Care Disclosures No relevant financial relationships to disclose I will be discussing non-fda approved indications
More informationQUIZZES WITH ANSWERS FOR COLLECTING CANCER DATA: PHARYNX
QUIZZES WITH ANSWERS FOR COLLECTING CANCER DATA: PHARYNX MP/H Quiz 1. A patient presented with a prior history of squamous cell carcinoma of the base of the tongue. The malignancy was originally diagnosed
More informationFINE NEEDLE ASPIRATION OF ENLARGED LYMPH NODE: Metastatic squamous cell carcinoma
Case Scenario 1 HNP: A 70 year old white male presents with dysphagia. The patient is a current smoker, current user of alcohol and is HPV positive. A CT of the Neck showed mass in the left pyriform sinus.
More informationCombined chemoradiotherapy in the treatment of locally advanced non-small cell lung cancer
Journal of BUON 7: 47-51, 2002 2002 Zerbinis Medical Publications. Printed in Greece ORIGINAL ARTICLE Combined chemoradiotherapy in the treatment of locally advanced non-small cell lung cancer S. Isaković-Vidović,
More informationMedicinae Doctoris. One university. Many futures.
Medicinae Doctoris The Before and The After: Can chemotherapy revise the trajectory of gastric and esophageal cancers? Dr. David Dawe MD, FRCPC Medical Oncologist Assistant Professor Disclosures None All
More informationjournal of medicine The new england Concurrent Chemotherapy and Radiotherapy for Organ Preservation in Advanced Laryngeal Cancer abstract
The new england journal of medicine established in 1812 november 27, 2003 vol. 349 no. 22 Concurrent Chemotherapy and Radiotherapy for Organ Preservation in Advanced Laryngeal Cancer Arlene A. Forastiere,
More informationDiagnosis and what happens after referral
Diagnosis and what happens after referral Dr Kate Newbold Consultant in Clinical Oncology The Royal Marsden Women's cancers Breast cancer introduction 1 Treatment Modalities Early stage disease -larynx
More informationRADIO- AND RADIOCHEMOTHERAPY OF HEAD AND NECK TUMORS. Zoltán Takácsi-Nagy PhD Department of Radiotherapy National Institute of Oncology, Budapest 1.
RADIO- AND RADIOCHEMOTHERAPY OF HEAD AND NECK TUMORS Zoltán Takácsi-Nagy PhD Department of Radiotherapy National Institute of Oncology, Budapest 1. 550 000 NEW PATIENTS/YEAR WITH HEAD AND NECK CANCER ALL
More informationDe-Escalate Trial for the Head and neck NSSG. Dr Eleanor Aynsley Consultant Clinical Oncologist
De-Escalate Trial for the Head and neck NSSG Dr Eleanor Aynsley Consultant Clinical Oncologist 3 HPV+ H&N A distinct disease entity Leemans et al., Nature Reviews, 2011 4 Good news Improved response to
More informationLarynx Hypopharynx. Therapy algorithms. Why larynx preservation at all? State of the art Jean Louis Lefebvre,Lille Jan Klozar,Prague
Larynx Hypopharynx Moderation Rainald Knecht,Hamburg State of the art Jean Louis Lefebvre,Lille Debate pro CRT Jan Klozar,Prague contra CRT Marshall Posner,Boston Clinical cases all Therapy algorithms
More informationOral Cavity Cancer Combined modality therapy
Oral Cavity Cancer Combined modality therapy Dr. Christos CHRISTOPOULOS Radiation Oncologist Head and Neck Cancers Centre Hospitalier Universitaire (C.H.U.) de Limoges, France Disclosure slide I have no
More informationQUIZZES WITH ANSWERS FOR COLLECTING CANCER DATA: PHARYNX
QUIZZES WITH ANSWERS FOR COLLECTING CANCER DATA: PHARYNX MP/H Quiz 1. A patient presented with a prior history of squamous cell carcinoma of the base of the tongue. The malignancy was originally diagnosed
More informationScottish Medicines Consortium
Scottish Medicines Consortium cetuximab 2mg/ml intravenous infusion (Erbitux ) (279/06) MerckKGaA No 9 June 2006 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationSaptarshi Ghosh*, Pamidimukkala Brahmananda Rao, P Ravindra Kumar, Surendra Manam
RESEARCH ARTICLE Concurrent Chemoradiation with Weekly Cisplatin for the Treatment of Head and Neck Cancers: an Institutional Study on Acute Toxicity and Response to Treatment Saptarshi Ghosh*, Pamidimukkala
More informationAdjuvant Chemotherapy in High Risk Patients after Wertheim Hysterectomy 10-year Survivals
6 Adjuvant Chemotherapy in High Risk Patients after Wertheim Hysterectomy 0-year Survivals V Sivanesaratnam,*FAMM, FRCOG, FACS Abstract Although the primary operative mortality following radical hysterectomy
More informationHPV and Head and Neck Cancer: What it means for you and your patients
HPV and Head and Neck Cancer: What it means for you and your patients Financial Disclosure: None November 8, 2013 Steven J. Wang, MD Associate Professor Department of Otolaryngology-Head and Neck Surgery
More informationThe Role of Concurrent Chemo-radiotherapy in Patients with Head and Neck Cancers: A Review
The Role of Concurrent Chemo-radiotherapy in Patients with Head and Neck Cancers: A Review M.D. Al-Sarraf 1 1 Williams Beaumont Hospital, Royal Oak, Michigan, USA Introduction In the past, radiotherapy
More informationEmerging Role of Immunotherapy in Head and Neck Cancer
Emerging Role of Immunotherapy in Head and Neck Cancer Jared Weiss, MD Associate Professor of Medicine and Section Chief of Thoracic and Head/Neck Oncology UNC Lineberger Comprehensive Cancer Center Copyright
More informationTHE IMPACT OF THE TIME FACTOR ON THE OUTCOME OF A COMBINED TREATMENT OF PATIENTS WITH LARYN- GEAL CANCER
THE IMPACT OF THE TIME FACTOR ON THE OUTCOME OF A COMBINED TREATMENT OF PATIENTS WITH LARYN- GEAL CANCER Piotr Milecki 1, Grażyna Stryczyńska 1, Aleksandra Kruk-Zagajewska 2 Department of Radiotherapy,
More informationConcurrent Chemoradiotherapy with Cisplatin and Docetaxel for Advanced Head and Neck Cancer. A Phase I Study
Concurrent Chemoradiotherapy with Cisplatin and Docetaxel for Advanced Head and Neck Cancer. A Phase I Study HIDENORI INOHARA 1, TAKEHIRO INOUE 2, SHIRO AKAHANI 1, YOSHIFUMI YAMAMOTO 1, YUKINORI TAKENAKA
More informationESOPHAGEAL CANCER. Dr. Paul Gardiner December 17, 2002 Discipline of Surgery Rounds
ESOPHAGEAL CANCER Dr. Paul Gardiner December 17, 2002 Discipline of Surgery Rounds ESOPHAGEAL CANCER I. EPIDEMIOLOGY INCIDENCE, DIAGNOSIS & STAGING II. TREATMENT OPTIONS Current role of induction therapies
More informationEsophageal cancer located at the cervical and upper thoracic
ORIGINAL ARTICLE Esophageal Cancer Located at the Neck and Upper Thorax Treated with Concurrent Chemoradiation: A Single- Institution Experience Shulian Wang, MD,* Zhongxing Liao, MD, Yuan Chen, MD, Joe
More informationUse of Larynx-Preservation Strategies in the Treatment of Laryngeal Cancer. American Society of Clinical Oncology Clinical Practice Guideline
Use of Larynx-Preservation Strategies in the Treatment of Laryngeal Cancer American Society of Clinical Oncology Clinical Practice Guideline Introduction ASCO convened an Expert Panel to develop recommendations
More informationNorth of Scotland Cancer Network Clinical Management Guideline for Carcinoma of the Uterine Cervix
THIS DOCUMENT North of Scotland Cancer Network Carcinoma of the Uterine Cervix UNCONTROLLED WHEN PRINTED DOCUMENT CONTROL Prepared by A Kennedy/AG Macdonald/Others Approved by NOT APPROVED Issue date April
More informationTreatment outcomes and prognostic factors of gallbladder cancer patients after postoperative radiation therapy
Korean J Hepatobiliary Pancreat Surg 2011;15:152-156 Original Article Treatment outcomes and prognostic factors of gallbladder cancer patients after postoperative radiation therapy Suzy Kim 1,#, Kyubo
More informationTitle Cancer Drug Phase Status
Clinical Trial Identifier Title Cancer Drug Phase Status NCT01164995 Study With Wee-1 Inhibitor MK-1775 and Carboplatin to Treat p53 Mutated Refractory and Resistant Ovarian Cancer Epithelial Ovarian Cancer
More informationProtocol of Radiotherapy for Head and Neck Cancer
106 年 12 月修訂 Protocol of Radiotherapy for Head and Neck Cancer Indication of radiotherapy Indication of definitive radiotherapy with or without chemotherapy (1) Resectable, but medically unfit, or high
More informationLung Pathway Group Cisplatin & PO Vinorelbine in Non- Small Cell Lung Cancer (NSCLC)
Lung Pathway Group Cisplatin & PO Vinorelbine in Non- Small Cell Lung Cancer (NSCLC) Indication: First line in radical/induction treatment in locally advanced NSCLC First line palliative treatment in advanced/metastatic
More informationEFFICACY OF NECK DISSECTION FOR LOCOREGIONAL FAILURES VERSUS ISOLATED NODAL FAILURES IN NASOPHARYNGEAL CARCINOMA
ORIGINAL ARTICLE EFFICACY OF NECK DISSECTION FOR LOCOREGIONAL FAILURES VERSUS ISOLATED NODAL FAILURES IN NASOPHARYNGEAL CARCINOMA Raymond King Yin Tsang, FRCSEd, Joseph Chun Kit Chung, MRCSEd, Yiu Wing
More informationKatsuro Sato. Department of Speech, Language and Hearing Sciences, Niigata University of Health and Welfare, Niigata, Japan
Report Niigata Journal of Health and Welfare Vol. 12, No. 1 Retrospective analysis of head and neck cancer cases from the database of the Niigata Prefecture Head and Neck Malignant Tumor Registration Committee
More informationAdjuvant Therapy in Locally Advanced Head and Neck Cancer. Ezra EW Cohen University of Chicago. Financial Support
Adjuvant Therapy in Locally Advanced Head and Neck Cancer Ezra EW Cohen University of Chicago Financial Support This program is made possible by an educational grant from Eli Lilly Oncology, who had no
More informationThis LCD recognizes these two distinct treatment approaches and is specific to treatment delivery:
National Imaging Associates, Inc. Clinical guidelines STEREOTACTIC RADIOSURGERY (SRS) AND STEREOTACTIC BODY RADIATION THERAPY (SBRT) CPT4 Codes: 77371, 77372, 77373 LCD ID Number: L33410 J-N FL Responsible
More informationMUSCLE-INVASIVE AND METASTATIC BLADDER CANCER
MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER (Text update March 2008) A. Stenzl (chairman), N.C. Cowan, M. De Santis, G. Jakse, M. Kuczyk, A.S. Merseburger, M.J. Ribal, A. Sherif, J.A. Witjes Introduction
More informationCOMPARATIVE STUDY ON EFFICACY AND TOXICITY OF CHEMORADIOTHERAPY AND RADIOTHERAPY IN HEAD, NECK AND CERVIX CANCER PATIENTS
COMPARATIVE STUDY ON EFFICACY AND TOXICITY OF CHEMORADIOTHERAPY AND RADIOTHERAPY IN HEAD, NECK AND CERVIX CANCER PATIENTS E.Maheswari 1, G.R.Saraswathy 1, Santh Rani Thaakur 1, Narmada Sambhasivam 2. 1
More informationTHORACIC MALIGNANCIES
THORACIC MALIGNANCIES Summary for Malignant Malignancies. Lung Ca 1 Lung Cancer Non-Small Cell Lung Cancer Diagnostic Evaluation for Non-Small Lung Cancer 1. History and Physical examination. 2. CBCDE,
More informationA Prospective Phase II Trial of Deintensified Chemoradiation Therapy for Low Risk HPV Associated Oropharyngeal Squamous Cell Carcinoma
A Prospective Phase II Trial of Deintensified Chemoradiation Therapy for Low Risk HPV Associated Oropharyngeal Squamous Cell Carcinoma B. S. Chera 1, R. J. Amdur 2, J. E. Tepper 3, B. Qaqish 4, R. Green
More informationOral cancer: Prognosis & Treatment. Dr. Hani Al Sheikh Radhi
Oral cancer: Prognosis & Treatment Dr. Hani Al Sheikh Radhi Prognostic factors in Oral caner TNM staging T stage N stage M stage Site Histological Factors Vascular & Perineural Invasion Surgical Margins
More informationSurgical Margins in Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma
Surgical Margins in Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma Consensus update and recommendations, 2018 Head and Neck Steering Committee P. Gorphe *, F. Nguyen, Y. Tao, P. Blanchard,
More informationNICE guideline Published: 10 February 2016 nice.org.uk/guidance/ng36
Cancer of the upper aerodigestive e tract: assessment and management in people aged 16 and over NICE guideline Published: 10 February 2016 nice.org.uk/guidance/ng36 NICE 2018. All rights reserved. Subject
More informationStandard care plan for Carboplatin and Etoposide Chemotherapy References
CHEMOTHERAPY CARE PLAN Document Title: Document Type: Subject: Approved by: Currency: Carboplatin/Etoposide Chemotherapy Clinical Guideline Standard Care Plan 2 Years Review date: Author(s): Standard care
More informationUpdate on Neoadjuvant Chemotherapy (NACT) in Cervical Cancer
Update on Neoadjuvant Chemotherapy (NACT) in Cervical Cancer Nicoletta Colombo, MD University of Milan-Bicocca European Institute of Oncology Milan, Italy NACT in Cervical Cancer NACT Stage -IB2 -IIA>4cm
More informationClinical Policy: Cetuximab (Erbitux) Reference Number: PA.CP.PHAR.317
Clinical Policy: (Erbitux) Reference Number: PA.CP.PHAR.317 Effective Date: 01/18 Last Review Date: 11/17 Coding Implications Revision Log Description The intent of the criteria is to ensure that patients
More informationThe PARADIGM Study: A Phase III Study Comparing Sequential Therapy (ST) to Concurrent Chemoradiotherapy (CRT) in Locally Advanced Head and Neck Cancer
The PARADIGM Study: A Phase III Study Comparing Sequential Therapy (ST) to Concurrent Chemoradiotherapy (CRT) in Locally Advanced Head and Neck Cancer Robert I. Haddad, Guilherme Rabinowits, Roy B. Tishler,
More informationGoals and Objectives: Head and Neck Cancer Service Department of Radiation Oncology
Goals and Objectives: Head and Neck Cancer Service Department of Radiation Oncology The head and neck cancer service provides training in the diagnosis, management, treatment, and follow-up care of head
More informationCase Scenario 1. Pathology: Specimen type: Incisional biopsy of the glottis Histology: Moderately differentiated squamous cell carcinoma
Case Scenario 1 History A 52 year old male with a 20 pack year smoking history presented with about a 6 month history of persistent hoarseness. The patient had a squamous cell carcinoma of the lip removed
More informationOver the past decade, the treatment of squamous cell carcinoma
ORIGINAL RESEARCH A. Zima R. Carlos D. Gandhi I. Case T. Teknos S.K. Mukherji Can Pretreatment CT Perfusion Predict Response of Advanced Squamous Cell Carcinoma of the Upper Aerodigestive Tract Treated
More informationRole of PETCT in the management of untreated advanced squamous cell carcinoma of the oral cavity, oropharynx and hypopharynx
International Journal of Otorhinolaryngology and Head and Neck Surgery Dutta A et al. Int J Otorhinolaryngol Head Neck Surg. 2018 Mar;4(2):526-531 http://www.ijorl.com pissn 2454-5929 eissn 2454-5937 Original
More informationCURRENT STANDARD OF CARE IN NASOPHARYNGEAL CANCER
CURRENT STANDARD OF CARE IN NASOPHARYNGEAL CANCER Jean-Pascal Machiels Department of medical oncology Institut I Roi Albert II Cliniques universitaires Saint-Luc Université catholique de Louvain, Brussels,
More informationA phase II study of weekly paclitaxel and cisplatin followed by radical hysterectomy in stages IB2 and IIA2 cervical cancer AGOG14-001/TGOG1008
A phase II study of weekly paclitaxel and cisplatin followed by radical hysterectomy in stages IB2 and IIA2 cervical cancer AGOG14-001/TGOG1008 NCT02432365 Chyong-Huey Lai, MD On behalf of Principal investigator
More informationDocetaxel. Class: Antineoplastic agent, Antimicrotubular, Taxane derivative.
Docetaxel Class: Antineoplastic agent, Antimicrotubular, Taxane derivative. Indications: -Breast cancer: -Non small cell lung cancer -Prostate cancer -Gastric adenocarcinoma _Head and neck cancer Unlabeled
More informationRecent Advances in Oral Oncology
Recent Advances in Oral Oncology Alexander D Rapidis 1 and Crispian Scully 2 1. Chairman, Department of Head and Neck/Maxillofacial Surgery, Greek Anticancer Institute, Saint Savvas Hospital, Athens, and
More informationCANCERS of OROPHARYNX and HYPOPHARYNX. STAGING and TREATMENT
1 CANCERS of OROPHARYNX and HYPOPHARYNX STAGING and TREATMENT 2 1. Staging 2. General Principles of Treatment 3. Site Specific Treatment Guidelines 4. Selected Abstracts from Relevant Studies 3 1. Staging
More informationErbitux. Erbitux (cetuximab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.84 Subject: Erbitux Page: 1 of 6 Last Review Date: December 2, 2016 Erbitux Description Erbitux (cetuximab)
More informationJOURNAL SCAN FOR IJHNS
JOURNAL SCAN FOR IJHNS IJHNS Journal Scan for IJHNS Meta-analysis of Chemotherapy in Head and Neck Cancer (MACH-NC): An Update on 93 Randomized Trials and 17,346 Patients Jean-Pierre Pignon A, Aurélie
More information